TransMedics Group, Inc. (TMDX): Price and Financial Metrics


TransMedics Group, Inc. (TMDX): $28.82

-0.08 (-0.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TMDX POWR Grades


  • TMDX scores best on the Growth dimension, with a Growth rank ahead of 54.02% of US stocks.
  • TMDX's strongest trending metric is Stability; it's been moving down over the last 31 weeks.
  • TMDX's current lowest rank is in the Stability metric (where it is better than 6.47% of US stocks).

TMDX Stock Summary

  • TransMedics Group Inc's stock had its IPO on May 2, 2019, making it an older stock than merely 4.49% of US equities in our set.
  • With a price/sales ratio of 32.5, TransMedics Group Inc has a higher such ratio than 92.95% of stocks in our set.
  • In terms of volatility of its share price, TMDX is more volatile than 89.1% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to TransMedics Group Inc, a group of peers worth examining would be FLNT, JMIA, XGN, TMST, and PWFL.
  • TMDX's SEC filings can be seen here. And to visit TransMedics Group Inc's official web site, go to www.transmedics.com.

TMDX Valuation Summary

  • TMDX's EV/EBIT ratio is -34.5; this is 229.21% lower than that of the median Healthcare stock.
  • Over the past 27 months, TMDX's price/sales ratio has gone down 0.6.
  • TMDX's price/earnings ratio has moved down 11.3 over the prior 27 months.

Below are key valuation metrics over time for TMDX.

Stock Date P/S P/B P/E EV/EBIT
TMDX 2021-07-02 37.3 9.6 -33.8 -39.6
TMDX 2020-08-28 20.0 4.2 -13.9 -15.2
TMDX 2020-05-04 15.1 6.5 -10.6 -12.7
TMDX 2019-12-30 30.6 6.3 -16.7 -19.6
TMDX 2019-09-03 38.9 7.1 -21.3 -23.5
TMDX 2019-06-17 42.9 -2.8 -23.5 -27.6

TMDX Price Target

For more insight on analysts targets of TMDX, see our TMDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $53.00 Average Broker Recommendation 1.5 (Moderate Buy)

TMDX Stock Price Chart Interactive Chart >

Price chart for TMDX

TMDX Price/Volume Stats

Current price $28.82 52-week high $49.50
Prev. close $28.90 52-week low $11.51
Day low $28.18 Volume 168,071
Day high $29.50 Avg. volume 612,111
50-day MA $28.76 Dividend yield N/A
200-day MA $25.11 Market Cap 796.12M

TransMedics Group, Inc. (TMDX) Company Bio


TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.


TMDX Latest News Stream


Event/Time News Detail
Loading, please wait...

TMDX Latest Social Stream


Loading social stream, please wait...

View Full TMDX Social Stream

Latest TMDX News From Around the Web

Below are the latest news stories about TransMedics Group Inc that investors may wish to consider to help them evaluate TMDX as an investment opportunity.

TransMedics to Report Second Quarter 2021 Financial Results on August 5, 2021

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter after market close on Thursday, August 5, 2021. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

Yahoo | July 22, 2021

FDA Ad Com votes in favor of TransMedics' OCS Liver System

TransMedics Group (TMDX) announces that after review and discussion of its clinical evidence from the OCS Liver PROTECT trial, the FDA Advisory Committee has issued a favorable vote in support of approval of the OCS Liver System. The panel voted 14 to 0, that there is reasonable assurance that the...

Seeking Alpha | July 15, 2021

TransMedics Announces Positive FDA Advisory Committee Vote for the OCS Liver System

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that after review and discussion of TransMedics' clinical evidence from the OCS Liver PROTECT trial, the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee convened by the U.S. Food and Drug Administration ("FDA") has issued a favorable vote in support of app

Yahoo | July 15, 2021

TransMedics Group's stock is halted in advance of FDA committee meeting

Shares of TransMedics Group Inc. were halted on Wednesday in advance of an advisory committee meeting scheduled for the same day by the Food and Drug Administration. The committee is expected to review the company's premarket approval application for an investigational liver treatment device and then vote on whether the FDA should approve the system. The regulator is not required to follow the advice of the committee but often does. TransMedics' stock has soared 59.2% so far this year, while the

Yahoo | July 14, 2021

TransMedics Stock Trading Halted Today; FDA Advisory Committee to Review Premarket Approval Application for the OCS Liver System

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that Nasdaq has halted trading of the company's common stock.

Yahoo | July 14, 2021

Read More 'TMDX' Stories Here

TMDX Price Returns

1-mo -14.68%
3-mo -3.09%
6-mo 23.27%
1-year 65.35%
3-year N/A
5-year N/A
YTD 44.82%
2020 4.68%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7222 seconds.